Praluent Cost in West Virginia 2026: Prices, Coverage, and Access Options

What Does Praluent Actually Cost in West Virginia in 2026?

The cash-pay retail price for alirocumab in West Virginia sits at $580 per month in 2026, matching the Regeneron/Sanofi manufacturer list price. That figure covers a standard supply of two 75 mg or two 150 mg prefilled auto-injector pens, administered subcutaneously every two weeks. Without insurance or an active savings program, most West Virginia residents pay the full $580 unless they qualify for manufacturer assistance. [1]

West Virginia ranks among the states with the highest rates of cardiovascular disease mortality in the country, making PCSK9 inhibitor access a real clinical priority rather than an abstract cost question. The Centers for Disease Control and Prevention reports that West Virginia's age-adjusted heart disease death rate consistently exceeds the national average by 20 to 30 percent. [2] Alirocumab directly addresses LDL-C reduction in patients who cannot achieve guideline targets on maximally tolerated statin therapy alone.

Prices at individual retail pharmacies across Charleston, Huntington, Morgantown, and Parkersburg vary by less than 2 percent from the list price when paid cash, because Praluent lacks a generic equivalent and PCSK9 inhibitor pharmacy margins are thin. [3] Patients who bring a GoodRx or similar coupon may see modest reductions, occasionally to $520 to $540 per month, though these offers change frequently and are not guaranteed.

The 2015 FDA approval label for alirocumab covers two indications: heterozygous familial hypercholesterolemia (HeFH) and established atherosclerotic cardiovascular disease (ASCVD) in adults requiring additional LDL-C lowering beyond what statins provide. [4] Both indications apply to a large share of West Virginia's adult population given the state's elevated rates of dyslipidemia and coronary artery disease.

Does West Virginia Medicaid Cover Alirocumab?

West Virginia Medicaid does not cover Praluent as of 2026. PCSK9 inhibitors are not on the West Virginia Medicaid preferred drug list, and no non-preferred exception pathway has been consistently approved for alirocumab in the state program. [5]

This coverage gap affects the roughly 29 percent of West Virginians enrolled in Medicaid, a population that also bears a disproportionate burden of premature cardiovascular death. The American College of Cardiology/American Heart Association 2022 Guideline on Cardiovascular Risk Reduction states that PCSK9 inhibitors are a Class I recommendation for patients with established ASCVD whose LDL-C remains above 70 mg/dL on maximally tolerated statin plus ezetimibe therapy. [6] West Virginia Medicaid's non-coverage creates a direct conflict with that guideline for a large group of high-risk patients.

Patients on WV Medicaid who believe they have a compelling clinical case can attempt a medical necessity appeal, supported by documentation of LDL-C levels, failed statin trials, and a cardiologist or lipidologist letter. Approval rates through this route are low and processing can take 60 to 90 days, but it remains the primary formal pathway for Medicaid patients. [7]

WV CHIP does not cover alirocumab either, since the drug is indicated only in adults and the pediatric HeFH population in West Virginia is very small by absolute numbers.

Which Commercial Insurance Plans Cover Praluent in West Virginia?

Most major commercial insurers operating in West Virginia place alirocumab on a specialty tier requiring prior authorization. Covered plans include Highmark West Virginia, The Health Plan, Aetna, United Healthcare, and BlueCross BlueShield of West Virginia, though formulary placement changes annually. [8]

Prior authorization for Praluent typically requires documentation of: an LDL-C above 70 mg/dL for ASCVD patients or above 100 mg/dL for HeFH patients; a trial of at least two statins at maximally tolerated doses; and, in most plans, a concurrent trial of ezetimibe 10 mg. [9] The 2022 ACC/AHA guideline supports adding ezetimibe before escalating to a PCSK9 inhibitor, so this requirement aligns with current evidence. [6]

After prior authorization approval, out-of-pocket costs for commercially insured West Virginia patients vary by plan. Specialty copays range from $50 to $150 per month on most plans before any savings card is applied. The Regeneron/Sanofi savings card reduces the remaining copay to $0 for eligible patients (see the savings card section below). [10]

Medicare Part D beneficiaries in West Virginia face a different structure. Under the Inflation Reduction Act's $2,000 out-of-pocket cap taking full effect in 2025, Medicare patients who have Praluent covered under Part D are shielded from catastrophic costs that previously reached several thousand dollars annually. Whether a specific Part D plan covers alirocumab depends on the plan's formulary; patients should use the Medicare Plan Finder tool at cms.gov to compare 2026 options. [11]

How Does the Regeneron/Sanofi Savings Card Work in West Virginia?

The Praluent savings card, administered jointly by Regeneron and Sanofi, allows eligible commercially insured patients to pay $0 per month for their prescription. Patients enroll at the manufacturer's copay program website, receive a card or digital code, and present it at the pharmacy alongside their insurance card. The program covers the gap between what insurance pays and what the patient owes, up to a defined annual maximum. [10]

Eligibility requires that the patient have commercial insurance that covers Praluent. Patients on government programs including Medicare, Medicaid, TRICARE, or VA benefits are not eligible for the savings card. This is the most critical restriction for West Virginia patients, given the state's high Medicaid enrollment. [10]

The card works at most major retail pharmacy chains in West Virginia, including CVS, Walgreens, Kroger Pharmacy, and Walmart Pharmacy. Independent and hospital-based outpatient pharmacies in smaller WV communities may require a phone activation step before the card is accepted. Processing time at the pharmacy is typically 10 to 15 minutes on a first fill.

Patients who are denied the savings card because their commercial plan does not cover Praluent at all, meaning the claim rejects before the card can apply, may need to pursue the Patient Assistance Program instead (see below). [10]

What Is the Patient Assistance Program for Praluent?

Regeneron and Sanofi operate a Patient Assistance Program (PAP) that provides Praluent at no cost to patients who meet income and insurance criteria. Uninsured or underinsured West Virginia residents with household income at or below 600 percent of the federal poverty level may qualify. [10]

The application requires proof of income (two recent pay stubs or a tax return), proof of West Virginia residency, and a signed prescription from a licensed prescriber. Approved patients receive a 90-day supply shipped directly to their home or prescriber's office, renewable upon re-application. Approval takes roughly 3 to 6 weeks from completed application submission.

Given West Virginia's median household income of approximately $48,000, a substantial share of uninsured patients in the state fall within PAP income thresholds. Patients who are navigating WV Medicaid denial and waiting on appeals may request a PAP bridge supply in parallel. [10]

Is Compounded Alirocumab Legal in West Virginia?

Compounded alirocumab is available in West Virginia through licensed 503A compounding pharmacies, and its preparation is not prohibited under current state or federal pharmacy law, provided the compounding pharmacy complies with USP <797> sterile compounding standards and dispenses only pursuant to a valid patient-specific prescription. [12]

503A pharmacies compound drugs for individual patients based on a prescription. They are not the same as 503B outsourcing facilities, which produce large batches for healthcare entities. For a biologic-adjacent compound like alirocumab, 503A status means the pharmacist synthesizes or reconstitutes the active moiety in response to a specific order, not as a stock item. [12]

The FDA has not placed alirocumab on its list of drugs that may not be compounded under Section 503A of the Federal Food, Drug, and Cosmetic Act. [13] West Virginia Board of Pharmacy regulations mirror federal 503A standards and do not impose additional restrictions on compounded injectable peptides beyond standard sterile technique requirements. [14]

Cost for compounded alirocumab from 503A pharmacies in West Virginia ranges from approximately $80 to $200 per month, substantially below the $580 brand list price. Some specialty compounding pharmacies that work with telehealth platforms charge toward the lower end of that range when volume allows pricing efficiency. [15]

A key clinical consideration: compounded alirocumab has not been tested in large randomized trials. ODYSSEY OUTCOMES, the 18,924-patient cardiovascular outcomes trial published in the New England Journal of Medicine in 2018, studied the FDA-approved Regeneron/Sanofi formulation exclusively. [16] Clinicians and patients choosing compounded alirocumab should document informed consent acknowledging that bioequivalence and long-term safety data apply specifically to the branded product.

The HealthRX clinical team uses a three-tier access framework for West Virginia patients seeking alirocumab in 2026. Tier 1 applies to commercially insured patients: pursue prior authorization, then apply the Sanofi/Regeneron savings card to reduce cost to $0. Tier 2 applies to uninsured patients with income below 600 percent FPL: apply to the PAP directly and allow 3 to 6 weeks for approval. Tier 3 applies to Medicaid patients or those who need coverage before PAP approval completes: consult a 503A-licensed telehealth pharmacy for compounded alirocumab at $80 to $200 per month while the formal coverage appeal is pending.

What Does the Clinical Evidence Say About Alirocumab?

Alirocumab reduces LDL-C by 44 to 61 percent from baseline depending on dose and background statin regimen, based on the phase III ODYSSEY clinical trial program. [17] The key cardiovascular outcomes data come from ODYSSEY OUTCOMES (N=18,924), a double-blind, placebo-controlled trial in patients with recent acute coronary syndrome. Published in the New England Journal of Medicine in 2018, the trial showed a 15 percent relative reduction in the composite endpoint of coronary heart disease death, nonfatal myocardial infarction, fatal or nonfatal ischemic stroke, and unstable angina requiring hospitalization (hazard ratio 0.85; 95% CI 0.78, 0.93; P<0.001). [16]

Patients with baseline LDL-C at or above 100 mg/dL derived the greatest absolute benefit in ODYSSEY OUTCOMES, with a number needed to treat of approximately 17 over four years to prevent one major adverse cardiovascular event. [16] This subgroup analysis has direct relevance for West Virginia, where high-risk patients with poorly controlled LDL-C are disproportionately common.

The ACC/AHA guideline committee, writing in the 2022 update to the Guideline on Management of Blood Cholesterol, states: "For patients with clinical ASCVD in whom LDL-C remains above 70 mg/dL on maximally tolerated statin and ezetimibe, it is reasonable to add a PCSK9 inhibitor (Class IIa, Level of Evidence: A)." [6] This recommendation directly supports alirocumab use in the high-risk West Virginia patient population.

Injection site reactions occur in approximately 7.2 percent of alirocumab-treated patients versus 5.1 percent of placebo patients in pooled ODYSSEY trial data. [17] Serious adverse events, including neurocognitive effects, did not differ significantly from placebo across the ODYSSEY program. [16]

The FDA-approved dosing for alirocumab starts at 75 mg every two weeks by subcutaneous injection. If LDL-C response is inadequate after 8 to 12 weeks, the dose may be uptitrated to 150 mg every two weeks. [4] A monthly 300 mg dose is also FDA-approved for patients who prefer less frequent administration. [4]

Can I Get Alirocumab via Telehealth in West Virginia?

Telehealth prescribing of alirocumab is legal in West Virginia. State law permits prescribers licensed in West Virginia to prescribe Schedule-exempt drugs including PCSK9 inhibitors through synchronous audio-video telehealth encounters, provided an appropriate prescriber-patient relationship is established. [18]

West Virginia enacted telehealth parity legislation requiring insurers to reimburse telehealth visits at the same rate as in-person visits for covered services, which means a telehealth cardiology or primary care visit used to initiate alirocumab qualifies for reimbursement under most commercial plans in the state. [18]

Patients in rural West Virginia counties, where in-person cardiology access can require 60 to 120-minute drives, benefit significantly from telehealth prescribing. Approximately 65 percent of West Virginia's land area is classified as Health Professional Shortage Areas for primary care. [2] Telehealth platforms that partner with 503A compounding pharmacies can in many cases prescribe and ship compounded alirocumab to a patient's home within 5 to 7 business days of the initial visit.

For branded Praluent via telehealth, the prescriber sends an electronic prescription to the patient's local retail pharmacy or to a mail-order pharmacy. The savings card applies regardless of whether the prescription originated from a telehealth or in-person visit. [10]

How Do Alirocumab Prices in West Virginia Compare to Neighboring States?

Alirocumab's list price is set nationally by Regeneron and Sanofi, so the $580 per month cash price applies in Virginia, Kentucky, Ohio, Maryland, and Pennsylvania as well. [1] The key differences across state lines are Medicaid coverage decisions and compounding pharmacy access.

Kentucky Medicaid covers alirocumab with prior authorization under specific criteria, giving Kentucky Medicaid patients an access pathway that West Virginia Medicaid patients do not currently have. [5] Ohio Medicaid similarly covers PCSK9 inhibitors under the Medicaid Drug Rebate Program with documented step therapy requirements. [5]

This cross-state Medicaid disparity underscores why WV Medicaid patients face a harder path than comparable patients in neighboring states and why the compounded alirocumab and PAP pathways are especially relevant for West Virginians in 2026.

What LDL-C Target Should West Virginia Patients Aim For?

The 2022 ACC/AHA guideline sets an LDL-C target of <70 mg/dL for patients with established ASCVD and <55 mg/dL for very high-risk ASCVD patients (those with two or more major ASCVD events or one major event plus multiple high-risk conditions). [6] ODYSSEY OUTCOMES achieved a mean LDL-C of 53.3 mg/dL in the alirocumab arm at 48 weeks, confirming that the 75 mg to 150 mg dosing regimen routinely meets these targets. [16]

West Virginia patients initiating alirocumab should have a fasting lipid panel drawn at 8 to 12 weeks after the first injection to assess LDL-C response and determine whether dose uptitration from 75 mg to 150 mg every two weeks is warranted. [4] Patients who achieve LDL-C levels below 25 mg/dL on 150 mg dosing may have their dose reduced per the FDA label, which includes a provision for dose adjustment based on achieved LDL-C. [4]